Comparing the current results to its competitors, Scholar Rock Holding reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 11.79 %, recorded in the same quarter.
February 21, 2025
: Scholar Rock, a biopharmaceutical company focused on pioneering therapies for spinal muscular atrophy (SMA) and other serious conditions, is set to present additional clinical data from its Phase 3 SAPPHIRE trial at the 2025 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference. This article delves into the implications of these forthcoming results for the treatment landscape of SMA and highlights Scholar Rock s commitment to addressing unmet medical needs through innovative therapeutic modalities. Spinal muscular atrophy (SMA) is a progressive neuromuscular disorder characterized by the degeneration of motor neurons in the spinal cord, leading to muscle weakness and atrophy. Current the...
November 1, 2024
On November 12, 2024, Scholar Rock Holding Corp is set to host a conference call to discuss its financial results for the third quarter of 2024, alongside an important business update. The call comes against a backdrop of significant financial losses, as the company reported a cumulative net loss of $204 million in the twelve months ending in the second quarter of 2024. This figure translates to a troubling negative return on investment (ROI) of -90.5%, placing Scholar Rock well below its peers in the healthcare sector.Despite these significant challenges, it is noteworthy that Scholar Rock s return on investment ranking has shown some gradual improvement in recent quarters. The company’s overall ranking i...
June 3, 2024
Scholar Rock s SRK-181 Shows Promise in Advanced Solid Tumor Treatment: Phase 1 DRAGON Trial Results Unveiled CAMBRIDGE, Mass. - Scholar Rock (NASDAQ: SRRK), a pioneering biopharmaceutical company dedicated to developing transformative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other severe conditions where protein growth factors play a crucial role, has recently announced promising results from its Phase 1 DRAGON proof-of-concept trial. The findings were presented at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting. Breakthrough in Cancer Treatment The Phase 1 DRAGON trial evaluated SRK-181, a highly selective inhibitor of latent transforming growth fact...
March 19, 2024
In a recent announcement, Scholar Rock, a leading late-stage biopharmaceutical company, shared their financial results and corporate updates for the full year 2023. The company is dedicated to developing innovative treatments for various severe diseases, with a particular focus on spinal muscular atrophy (SMA), cardiometabolic disorders, and conditions where protein growth factors play a significant role. This article will outline the key facts presented by Scholar Rock and assess their impact on the company s progress.Key Highlights and Financial Performance:Scholar Rock showcased significant advancements in their industry-leading antimyostatin pipeline. Antimyostatin agents are designed to inhibit the acti...
Publicly Traded Peers of Scholar Rock Holding Corp
Agenus Inc Share Performance
+3.50%
Over The Past 5 Days
Agenus Inc
Profile
Agenus Inc is a biotechnology company that primarily focuses on the discovery and development of immune-based therapies for cancer treatment. Their business model revolves around leveraging their proprietary technologies and capabilities to develop and commercialize therapeutic antibodies and vaccines. Agenus Inc also collaborates with other pharmaceutical companies through licensing agreements and partnerships to further advance their product pipeline.
Biogen Incs business model focuses on researching, developing, and commercializing innovative therapies primarily for neurological and neurodegenerative diseases, emphasizing advancements in precision medicine and patient care.
The business model of Blueprint Medicines Corporation revolves around the development and commercialization of precision therapies for patients with genomically defined cancers and rare diseases. They actively pursue a strategy of genomically targeted drug discovery and development, utilizing advanced technologies and clinical expertise to bring potentially life-changing treatments to market. The company focuses on creating value through strategic collaborations, licensing agreements, and the commercialization of their innovative therapies.
Cullinan Oncology Inc's business model focuses on developing innovative cancer treatments by identifying and acquiring promising drug candidates through collaborations and partnerships with academic institutions and biotechnology companies. They prioritize the advancement of these therapies towards clinical trials and commercialization, aiming to address unmet medical needs in the field of oncology.
Coherus Biosciences Inc is a biopharmaceutical company focused on developing and commercializing high-quality biosimilar therapeutics. Their business model revolves around leveraging their expertise in cell culture, protein purification, formulation development, and analytical methods to manufacture and market biosimilar products. By providing cost-effective alternatives to expensive biologic drugs, Coherus Biosciences aims to make healthcare more accessible and affordable for patients.
Sources:
Scholar Rock Holding Corp’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Scholar Rock Holding Corp versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
